Home Alzheimer’s Disease AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19

AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19

AstraZeneca plans to conduct a global clinical trial to assess the effect of acalabrutinib (Calquence) on the exaggerated immune response of patients who are severely ill with the coronavirus disease 2019 (COVID-19) infection, according to a press release.

The trial design was based on strong scientific and early clinical data on the Bruton’s tyrosine kinase (BTK) pathway and its role in the production of inflammatory cytokines. The trial hopes to evaluate safety and efficacy of adding acalabrutinib to best supportive care in an attempt to reduce mortality and assisted ventilation requirements for patients with strong COVID-19 symptoms.

“With this trial we are responding to the novel insights of the scientific community and hope to demonstrate that adding Calquence to best supportive care reduces the need to place patients on ventilators and improves their chances of survival,”…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments